Schrödinger（SDGR.US）把两个临床前免疫/炎症小分子项目（SDGR-4594、SDGR-8139）出资给其与NEA、RA Capital共同创立的新公司Tectora，换取私募股权及或有里程碑与版税；Tectora同步完成5,500万美元A轮，未披露给SDGR的任何预付款

NEWS RELEASE




Schrödinger Announces Licensing and Collaboration
Agreement with Tectora Therapeutics, a New
Biotechnology Company It Co-founded to Advance
Immunology and In ammation Programs
2026-09-09

Tectora secures $55 million Series A investment from NEA and RA Capital Management

NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) today announced the formation of Tectora, a new
biotechnology company it co-founded with New Enterprise Associates (NEA) and RA Capital Management, focused
on developing innovative therapies for immunology and in ammation. Tectora concurrently closed a $55 million
Series A investment from NEA and RA Capital.

In connection with the transaction, Schrödinger contributed two early-stage small molecule programs (SDGR-4594
and SDGR-8139) and, in exchange, received an equity stake in Tectora and is also eligible to receive future
milestones and royalties. Tectora will partner with Schrödinger’s drug discovery experts and leverage Schrödinger’s
computational platform at scale to further advance these programs to clinical candidates.

“Schrödinger has a track record of creating and enabling programs for licensing to pharma companies or joining
forces with venture funds to build successful biotechnology companies such as Nimbus, Morphic, Structure and
Ajax. These partnerships have collectively generated over $750 million in proceeds to Schrödinger,” said Karen
Akinsanya, Ph.D., President, Therapeutics R&D, and Chief Strategy O cer, Partnerships, at Schrödinger. “We co-
founded Tectora with NEA and RA Capital to pair our breakthrough science with the dedicated capital and industry
expertise needed to rapidly advance these programs to patients.”

“As early-stage company builders we look for opportunities where exceptional science is paired with a motivated
1
entrepreneurial team,” said J.C. Lopez, Principal, New Enterprise Associates. “We believe the Tectora team, paired
with Schrödinger’s internal drug discovery team and industry-leading computational platform, will be able to
successfully advance programs against historically challenging immunology and in ammation targets.”

“We were drawn to the opportunity to leverage Schrödinger’s drug discovery expertise and capabilities to develop
therapeutics against high-value, validated targets,” said Jenna Hebert, Ph.D., Investment Director, RA Capital
Management. “Immunology and in ammation remain areas of immense unmet patient need, and we are excited to
co-found Tectora to advance these high-potential programs through preclinical development and into the clinic.”

About Tectora Therapeutics
Tectora Therapeutics is a privately held biotechnology company developing di erentiated oral medicines for
immune mediated diseases. The company is focused on translating clinically validated biology into convenient oral
medicines for patients. By partnering with Schrödinger, Tectora leverages advanced computational tools, drug
discovery expertise, and preclinical capabilities to advance its initial programs. Tectora aims to build a broad
pipeline of medicines for patients with signi cant unmet need. For more information, please visit
https://tectoratx.com/.

About Schrödinger
Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of
novel, highly optimized molecules for drug development and materials design. Schrödinger’s software platform is
built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial
companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a
portfolio of collaborative and proprietary programs. To learn more, visit www.schrodinger.com, follow us on
LinkedIn, or visit our blog, Extrapolations.com.

About New Enterprise Associates
New Enterprise Associates, Inc. (NEA) is a global venture capital rm focused on helping entrepreneurs build
transformational businesses across multiple stages, sectors and geographies. Founded in 1977, NEA has more than
$35 billion in assets under management as of December 31, 2025, and invests in technology and healthcare
companies at all stages in a company’s lifecycle, from seed stage through IPO. The rm's long track record of
investing includes more than 285 portfolio company public listings and more than 510 mergers and acquisitions.
For more information, please visit www.nea.com.

About RA Capital Management
Founded in 2004, RA Capital Management is a multi-stage investment manager dedicated to evidence-based
investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and
funds innovative companies, from private seed rounds to public follow-on nancings, allowing management teams
2
to drive value creation from inception through commercialization and beyond. RA Capital’s knowledge engine is
guided by TechAtlas, its science- rst internal research division. Raven, RA Capital’s healthcare incubator, o ers
entrepreneurs and innovators a comprehensive business-building platform for biomedical innovation. RA Capital
has over 250 employees and $16 billion in assets under management as of June 30, 2026. Learn more at
www.racap.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation
Reform Act of 1995 including, but not limited to those statements regarding our ability to realize potential
milestone and royalty payments, the risk that we may not realize the expected bene ts of the collaboration with
Tectora, the initiation, timing, progress and results of Tectora’s initial programs, and the potential advantages of
Schrödinger’s computational platform. Statements including words such as “aim,” “anticipate,” “believe,”
“contemplate,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would” and statements in the future tense are forward-looking statements. These
forward-looking statements re ect Schrödinger’s current views about its plans, intentions, expectations, strategies
and prospects, which are based on the information currently available to the company and on assumptions the
company has made. Actual results may di er materially from those described in these forward-looking statements
and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond
Schrödinger’s control, including the expected bene ts of, and opportunities related to, the collaboration with
Tectora, Tectora’s ability to obtain su cient funding and advance its initial programs, the uncertainties inherent in
drug development and commercialization, uncertainties associated with the regulatory review of clinical trials and
applications for marketing approvals, its ability to further develop its computational platform, its reliance on third-
party collaborators, and the ability of Schrödinger and Tectora to retain and hire key personnel, and other risks
detailed under the caption “Risk Factors” and elsewhere in the company’s Securities and Exchange Commission
lings and reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, led with the
Securities and Exchange Commission on August 5, 2026, as well as future lings and reports by the company. Any
forward-looking statements contained in this press release speak only as of the date hereof. Except as required by
law, Schrödinger undertakes no duty or obligation to update any forward-looking statements contained in this
press release as a result of new information, future events, changes in expectations or otherwise.

Jaren Madden (Investors and Media)
Schrödinger, Inc.
jaren.madden@schrodinger.com
617-286-6264

Matthew Luchini (Investors)
3
Schrödinger, Inc.
matthew.luchini@schrodinger.com
917-719-0636

Theresa Masnik (Media)
SHIFT Communications
schrodingerpr@shiftcomm.com
212-229-1037

Source: Schrödinger




4